NextCure Announces Proposed Public Offering of Common Stock
November 12 2019 - 4:18PM
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical
company committed to discovering and developing novel,
first-in-class immunomedicines to treat cancer and other
immune-related diseases, today announced a proposed public offering
of 3,200,000 shares of its common stock. In addition, NextCure
intends to grant the underwriters a 30-day option to purchase up to
an additional 480,000 shares of its common stock at the public
offering price, less underwriting discounts and commissions. All of
the common stock to be sold in the offering will be offered by
NextCure. The offering is subject to market and other conditions,
and there can be no assurance as to whether or when the offering
may be completed, or the actual size or terms of the offering.
Morgan Stanley, BofA Securities and Piper Jaffray & Co. are
acting as joint book-running managers for the offering. Needham
& Company and BTIG are acting as co-managers for the
offering.
A registration statement relating to the shares being sold in
the offering has been filed with the Securities and Exchange
Commission but has not yet become effective. The offering will be
made only by means of a prospectus. Copies of the preliminary
prospectus relating to the offering may be obtained by visiting
EDGAR on the SEC’s website at www.sec.gov or from: Morgan Stanley
& Co. LLC, Attention: Prospectus Department, 180 Varick Street,
2nd Floor, New York, New York 10014; BofA Securities,
NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte,
North Carolina 28255-0001, Attn: Prospectus Department, or by email
at dg.prospectus_requests@baml.com; Piper Jaffray & Co., 800
Nicollet Mall, J12S03, Minneapolis, Minnesota, 55402, Attention:
Prospectus Department, by telephone at (800) 747-3924 or by email
at prospectus@pjc.com.
These securities may not be sold nor may offers to buy these
securities be accepted prior to the time that the registration
statement becomes effective. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of, these securities in any state or
other jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About NextCure, Inc.NextCure is a
clinical-stage biopharmaceutical company committed to discovering
and developing novel, first-in-class immunomedicines to treat
cancer and other immune-related diseases.
Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com
Media Inquiries
Shai Biran, Ph.D.
MacDougall
(781) 235-3060
sbiran@macbiocom.com
NextCure (NASDAQ:NXTC)
Historical Stock Chart
From Aug 2024 to Sep 2024
NextCure (NASDAQ:NXTC)
Historical Stock Chart
From Sep 2023 to Sep 2024